

## PROXY: GENOMMA LAB INFORMS THE AMOUNT TO BE PROPOSED TO THE SHAREHOLDER'S MEETING FOR THE 2025 SHARE BUYBACK PROGRAM

Mexico City, April 08, 2025— **Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB)** (“Genomma Lab” or the “Company”), one of the leading pharmaceutical and personal care products companies in Mexico with an increasing international presence, informs the maximum amount to be proposed, to the Annual General Shareholders Meeting, for the 2025 share buyback program. Please note that the Company has never executed the full amount authorized. Management has always been very prudent with the use of cash flow.

In accordance with section IV, Article 56 of the Mexican Securities Market Law, the maximum amount to be proposed to the shareholders meeting, which would be allocated for the repurchase of Company shares, during 2025, will be an amount equal to the balance of the total accumulated distributable net profits of Genomma Lab for the fiscal year ending on December 31, 2024, less the amount separated from such profits to declare any dividends as approved by the Shareholders Meeting, if any.

For further understanding of the Article 56, section IV of the Mexican Securities Market Law states (Spanish Version):

Sección VI	
De las operaciones que las sociedades anónimas bursátiles realizan con acciones de su capital social o títulos de crédito que las representen	
<b>Artículo 56.-</b> Las sociedades anónimas bursátiles podrán adquirir las acciones representativas de su capital social o títulos de crédito que representen dichas acciones, sin que sea aplicable la prohibición establecida en el primer párrafo del artículo 134 de la Ley General de Sociedades Mercantiles, siempre que:	
<b>IV.</b>	La asamblea general ordinaria de accionistas acuerde expresamente, para cada ejercicio, el monto máximo de recursos que podrá destinarse a la compra de acciones propias o títulos de crédito que representen dichas acciones, con la única limitante de que la sumatoria de los recursos que puedan destinarse a ese fin, en ningún caso exceda el saldo total de las utilidades netas de la sociedad, incluyendo las retenidas.

For the last 5 fiscal years, the total amount invested in the share buyback program has not exceeded 10% of the total amount authorized each year by the Annual General Shareholders Meeting (AGSM). Please note that the Company cancelled 28 and 20 million shares during the 2023 and 2024 AGSMs respectively.

Year	Shares Repurchased	Total Investment (MXN)	% of Total Shares Outstanding
2020	605,000	\$11,078,191	0.1%
2021	7,896,875	\$155,924,884	0.8%
2022	38,927,360	\$618,199,867	3.7%
2023	16,411,633	\$231,944,320	1.6%
2024	3,726,457	\$63,957,709	0.4%

In accordance with applicable law, the statutory legal reserve is already fully funded by an amount of \$442 million Mexican Pesos. The Board of Directors intends a holding limit of up to 10% of Company's issued share capital in treasury.

### About Genomma Lab Internacional

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Latin America. Genomma Lab develops, sells and markets a broad range of Premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has a sound business model through a unique combination of a new product development process, consumer oriented marketing, a broad retail distribution network and a low-cost, highly flexible supply chain operating model. For more information visit: [www.genommalab.com](http://www.genommalab.com)

Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker "**LABB**" (Bloomberg: **LABB:MM**).

### Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.